Jazz Pharmaceuticals PLC (JAZZ) — 10-Q Filings

10-Q Filings (6)

• Jazz Pharma Swings to Loss on Soaring R&D Costs, Revenue Up — Nov 5, 2025 Risk: high
  Jazz Pharmaceuticals plc reported a mixed financial performance for the nine months ended September 30, 2025. Total revenues increased to $3,069,660,000 from $2
• Jazz Pharma Q2 Revenue Dips Slightly to $950M Amidst Stable Product Sales — Aug 6, 2025 Risk: medium
  Jazz Pharmaceuticals plc reported total revenues of $950.0 million for the three months ended June 30, 2025, a decrease from $960.0 million in the prior-year pe
• Jazz Pharma Q1 2025 Sales Dip — May 7, 2025 Risk: medium
  Jazz Pharmaceuticals plc filed its 10-Q for the period ending March 31, 2025. The company reported net product sales of $854.4 million for the first quarter of
• Jazz Pharma Q3 Sales Rise to $930.5M — Nov 7, 2024 Risk: low
  Jazz Pharmaceuticals plc reported its third-quarter 2024 results, with product sales for the three months ended September 30, 2024, reaching $930.5 million, an
• Jazz Pharma Q2 2024: Sales Hit $513M — Aug 1, 2024 Risk: medium
  Jazz Pharmaceuticals plc reported its financial results for the second quarter of 2024, ending June 30, 2024. The company's net product sales for the second qua
• Jazz Pharmaceuticals plc Files 10-Q for Period Ending March 31, 2024 — May 2, 2024 Risk: low
  Jazz Pharmaceuticals plc (JAZZ) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Jazz Pharmaceuticals plc filed a 10-Q report for the quarter ended

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX